Background-Autologous hematopoietic stem cell transplantation (AHCT) improves survival in patients with multiple myeloma (MM) but is associated with morbidity and non-relapse mortality (NRM). Hematopoietic cell transplant comorbidity index (HCT-CI) was shown to predict risk of NRM and survival after allogeneic transplantation. We tested the utility of HCT-CI as a predictor of NRM and survival in patients with MM undergoing AHCT.
INTRODUCTION
High-dose melphalan (MEL) followed by autologous hematopoietic stem cell transplant (AHCT) is widely used to treat patients with multiple myeloma [MM]. 1, 2 Risk stratification and selection of patients prior to AHCT depends on comorbidities, performance score and age. 3 Uncertainty regarding how well older patients tolerate high-dose therapy has resulted in arbitrary age limits for performing AHCT. 3 The discrepancy between chronological and physiological age is likely influenced by the comorbidities. Consequently, comorbidity indices have been developed to assess the tolerability of the allogeneic and autologous transplants. The Charlson Comorbidity Index (CCI) has previously been used to predict mortality in cancer patients. 4 However, CCI included some rarely encountered comorbidities (such as dementia, AIDS, and metastatic cancer) among transplant patients and it lacks precise grading (as mild, moderate and severe) of some comorbidities (renal, hepatic and pulmonary functions). The hematopoietic cell transplant comorbidity index (HCT-CI) scoring system was subsequently developed by Sorror et al. and shown to be a better predictor of non-relapse mortality (NRM) after allogeneic transplants in patients with hematological malignancies including MM. [5] [6] [7] [8] [9] HCT-CI is a weighted index of 15 pretransplant comorbidities that includes laboratory evaluation of some comorbidities. Patients may have a minimum score of 0 and maximum score of 26 (Table 1S) [supplementary table] noting mutually exclusive scores (mild/moderate hepatic and moderate/severe pulmonary comorbidity score). 8, 10 MM is associated with a variety of end-organ compromise such as renal dysfunction, bone disease, neuropathy, and anemia and repeated infections. 11 It is possible that the tolerance of myeloma patients to high-dose therapy with AHCT is different from patients with other hematological neoplasms. Identifying a co-morbidity scoring system for tolerability of AHCT in patients with MM helps selection of patients for such intensive therapy. In this study, we used the database of the CIBMTR to study the impact of the pre-transplant HCT-CI on the clinical outcome after AHCT of MM patients; specifically non-relapse mortality (NRM) and overall survival (OS).
PATIENTS AND METHOD

Data Source
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry (IBMTR), the Autologous Blood and Marrow Transplant Registry (ABMTR), and the National Marrow Donor Program. It comprises a voluntary group of more than 450 transplant centers worldwide that contribute their detailed data on consecutive allogeneic and autologous transplants to a statistical center at the Health Policy Institute of the Medical College of Wisconsin in Milwaukee or the National Marrow Donor Program Coordinating Center in Minneapolis, Minnesota. Participating centers are required to register all transplants done consecutively. Compliance of the participating centers is monitored by periodic on-site audits. Patients are followed up longitudinally, with yearly data update. Computerized checks for errors, physicians' review of submitted data, and on-site audits of participating centers altogether ensure data quality. Observational studies conducted by the CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the institutional review board and the privacy officer of the Medical College of Wisconsin. All CIBMTR centers contribute to the registration data. Research data are collected on a subset of registered patients and include detailed disease and pre-transplant and post-transplant clinical information.
Patients
A total of 1156 patients who underwent AHCT (including tandem and second salvage transplant) between 2007 and 2010 were identified who had received high-dose melphalan alone as a conditioning regimen and had available complete information of co-morbidity scores. All the patients who were alive had at least 100-day follow-up.
Assessment of comorbidities
Information of the comorbidities was obtained from prospectively reported records in the CIBMTR database. All patients were assigned an HCT-CI score based on the criteria reported by Sorror et al 8 (table 1S) [supplementary table] . A total of 489 patients had HCT-CI score 0 (366 patients had no comorbidity and 123 patients had comorbidities not included in the HCT-CI schema). The remaining 667 patients had at least one of the HCT-CI comorbidities and received a score ranging from 1 to 11. Distribution of HCT-CI scores of the study cohort is shown in figure 1.
Statistical method
Descriptive statistics were used to summarize the characteristics of the study population. Median value and range were used for continuous variables. Frequency and percentage were used for categorical variables. Group comparisons were done by Kruskal-Wallis test, chi-square test, and Fisher exact test. Survival probabilities were calculated by using the Kaplan-Meier estimator with the variance estimated by Greenwood's formula. NRM was defined as mortality after transplant in the absence of disease relapse or progression. Thus the cumulative incidence probabilities for NRM were calculated accounting for relapse as a competing risk. Point-wise comparison and log rank analysis were used to analyze the NRM and survival of different groups. Multivariate analysis was performed using Cox proportional hazard regression model. Variables analyzed included HCT-CI, age, gender, myeloma subtype and stage, melphalan dose, number of chemotherapy regimens before transplant, disease sensitivity before transplant, KPS and time from diagnosis to transplant (table 2S) [supplementary table] . Forward stepwise variable selection at a 0.05 significance level was used to identify covariates. In the model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate and graphical methods. All variables considered in the multivariate analysis satisfied the proportionality assumption. All computations were made using the statistical package SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Patient characteristics
Subjects were classified into 3 groups based on HCT-CI scores; low risk (HCT-CI=0), intermediate risk (HCT-CI 1-2), and high risk (HCT-CI >2). Characteristics of the patients in the 3 groups are shown in Table 1 . The distribution of the comorbidities among the 3 subgroups of patients is shown in table 3S [supplementary table] .
The HCT-CI score was 0 and 1 in 42% and 18% respectively and 2, 3 and > 3 in 13%, 13% and 14% respectively. The most common comorbidities included pulmonary, diabetes, obesity, psychiatric, cardiac, renal and history of prior solid neoplasm.
Males (p=0.006), African Americans (p=0.02) and patients with lower KPS performance scores (p<0.001) had significantly higher HCT-CI scores. Patients with higher HCT-CI were more likely to receive a lower melphalan dose (140mg/m 2 ; 22% with HCT-CI >2 vs. 10% with HCT-CI =0, p<0.001). More patients with higher HCT-CI scores were transplanted in recent years (p<0.001). Other patient-, disease-or transplant-related factors did not differ significantly between the 3 groups.
Survival analysis
The 3-year OS was 76% [95% CI: 70-80%] for HCT-CI=0 group, 71% [95% CI: 77-84%] for HCT-CI > 0 group (p=0.02) (figure 2). There was no difference in OS among patients who received MEL dose of 140 and 200 mg/m 2 (data not shown). Patients with higher HCT-CI were more likely to receive MEL 140 mg/m 2 , however, there was no difference in OS in this subset of patient (with HCT-CI > 0) receiving lower MEL doses (p=0.68) ( figure 3) .
Treatment Related Mortality
The cumulative incidence of TRM at 1 year was 2% [95% CI: 1-4%] for HCT-CI 0 group. For HCTCI-CI >2, TRM at 1 year was 2% [95% CI: 1-4%] respectively. The main cause of death in the cohort was disease relapse and progression (table 2).
Multivariate analyses
OS was worse in the groups with HCT-CI 1-2 (RR 1.37 [95% CI: 1.01-1.87], p=0.04) and HCT-CI >2 (RR 1.5 [95% CI: 1.09-2.08], p=0.01) when compared with HCT-CI 0 group. There was no difference in OS between the groups with HCT-CI >2 and HCT-CI 1-2 (RR 1.09 [1.79-1.52], p=0.6). Since there was no difference in survival between the groups with HCT-CI of 1-2 and >2 these groups were combined in subsequent analyses designated as HCT-CI >0 (N=667) and were compared with the group with HCT-CI of 0 (N=489). Variables included in the multivariate analysis are listed in table 2S [supplementary table] and results are summarized in Table 3 .
Significant predictors of worse OS were HCT-CI >0 (RR: 1.33, [95% CI: 1.01-1.75] p=0.04) (figure 4), IgA myeloma (RR: 1.64 [1.21-2.21]; p=0.001), >1 chemotherapy regimen before transplant (RR: 1.47; p=0.007), refractory MM at transplant (RR: 1.78; p<0.001), and KPS <90 (RR: 1.6; p<0.001). The HCT-CI (0 vs. >0) did not influence OS in patients who were > 65 years at the time of transplant (p = 0.16). Age did not show a statistically significant influence on OS or NRM.
NRM was higher in patients who received transplant > 12 month after initial diagnosis (RR: 2.09 [95% CI: 1.16-3.75], p=0.01). HCT-CI did not predict NRM.
DISCUSSION
We sought to evaluate the impact of medical comorbidities on the outcome of MM patients undergoing AHCT using the HCT-CI, an instrument validated predominantly in allogeneic transplant population. Although higher HCT-CI scores did not affect NRM, they were associated with inferior OS. The paucity of events of TRM after AHCT for MM limits our ability to detect the effect of higher HCT-CI scores on this outcome.
Interestingly HCT-CI remains a robust factor predictive of lower OS after AHCT. This association is likely multifactorial. Since NRM was not increased among sub-groups with higher scores, these patients eventually succumbed to MM progression. It may be hypothesized that aggressive disease resulted in more comorbidities (such as renal or cardiac dysfunction or infections) which contributed to higher HCT-CI and also resulted in inferior OS. Our data show the prevalent practice MEL dose reduction (< 200 mg/m 2 ) in patients with higher HCT-CI scores. However, the mere use of lower dose of MEL was not correlated to inferior survival by multivariate analysis and this practice perhaps permitted a larger number of patients to proceed to AHCT.
Other factors that also independently contributed to inferior OS in our study were the use of more than one line of chemotherapy regimen before transplant, refractory disease at the time of transplant and KPS < 90. The finding that lower KPS is a stronger predictor of inferior OS is similar to previously reported data in allogeneic transplant. 12 Although IgA myeloma is traditionally associated with worse outcome, it has not been shown previously to influence survival after AHCT. 13, 14 Our finding of inferior OS in patients with IgA disease warrants further investigations as these patients may derive more benefit from maintenance therapy after transplant.
In our cohort, NRM was higher in patients who received AHCT > 12 month after initial diagnosis (RR: 2.09 [95% CI: 1.16-3.75], p=0.01). This may be attributed to delaying transplant in physically unfit patients until improvement of KPS or controlling comorbid illnesses or disease complications. Our study cohort also included patients who had double (either tandem or salvage) AHCT (19% of patients with HCT-CI =0 and 13% with HCT-CI >0). The use of double transplantation was similar among patients who received transplant > 12 months and < 12 months from diagnosis (12% and 17% respectively). Thus more intense AHCT therapy per se cannot explain the NRM difference between these 2 groups.
Previous smaller studies have evaluated the influence of comorbidities on outcomes of AHCT in MM and lymphoma. A series of 126 patients who underwent AHCT for MM found that any comorbidity scored in CCI or HCT-CI to be associated with increased transplant morbidities (organ toxicity) and prolonged hospital stay. 15 Similar finding was also seen in patients with lymphoma. 16, 17 For example, a retrospective analysis of lymphoma patients undergoing AHCT showed that higher CCI score (and not age) was correlated with higher NRM and lower OS. 17 Our data from a large, multicenter cohort of patients treated with melphalan only as conditioning regimen suggests that AHCT for MM is safe even in those with higher HCT-CI. The use of HCT-CI that was initially validated in the setting of allogeneic transplant may be a weakness as it may not be the optimal index for evaluating MM patients undergoing AHCT. Our findings have important implications for the clinical practice of AHCT in MM. First, it does not appear that the use of the HCT-CI offers an advantage over performance status assessment in predicting risk of NRM in MM patients undergoing AHCT. Second, age and comorbidities did not seem to impact NRM, which supports the safety and continued use of melphalan based transplant in these populations. Third, KPS and the HCT-CI are both useful predictors of OS. These data are consistent with an International Myeloma Working Group (IMWG) analysis that suggested age (younger vs. older than 50 years) was not an independent predictor of survival for patients with MM receiving AHCT. 18 Most of the study patients were Caucasians (79%) and Black population represented 18%, while other minorities represented only 2%. Since some comorbidities may be more prevalent among certain ethnicities, these data are to be interpreted with caution in these ethnic groups.
Limitations inherent to our registry analyses include its retrospective nature and heterogeneity among practitioners in selecting MM patients for transplant. Thus selection bias in some centers may have precluded patients with certain comorbidities from having transplant.
In conclusion, a higher HCT-CI score did not predict NRM but was associated with inferior survival in patients with MM undergoing AHCT. KPS remains an important predictor of survival. Future studies are need to develop co-morbidity indices (that may include functional assessment such as KPS) and are more predictive of NRM after AHCT in MM patients.
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